<DOC>
	<DOCNO>NCT02401971</DOCNO>
	<brief_summary>Recent clinical study demonstrate reduction irinotecan ( CPT-11 ) gastrointestinal toxicity CPT-11 administer combination thalidomide patient diagnosis gastric cancer . The main purpose study investigate efficacy safety thalidomide CPT-11 advance gastric cancer . The investigator also manage find possible interaction CPT-11 pharmacokinetics thalidomide explain previously describe gastrointestinal toxicity reduction .</brief_summary>
	<brief_title>Irinotecan Plus Thalidomide Second Line Advanced Gastric Cancer</brief_title>
	<detailed_description>This prospective , randomize , multi-center , control clinical trial , aim evaluate efficacy tolerability thalidomide CPT-11 advance gastric cancer . A total 900 patient plan enrol study . Patients diagnosis advance gastric cancer randomize two group , treat thalidomide+ CPT-11 CPT-11 , respectively . The primary end point time progression ( TTP ) , secondary end point include efficacy , overall survival ( OS ) occurrence delay diarrhea .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>18y &lt; Age &lt; 75y Patients histologically proven tumor focus eligible protocol Measurable assessable disease At least 4 week since last chemotherapy ; chemotherapy regimens without Irinotecan No hepatic , renal hematopoietic dysfunction ; hemorrhage digestive tract , obstructive jaundice , gastrointestinal perforation obstruction ECOG PS:02 Expected OS â‰¥ 3 month obstruction digestive tract , thrombosis intolerant side effect treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Thalidomide</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Second Line</keyword>
</DOC>